Lucid Diagnostics Inc. (Nasdaq: LUCD) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), closed on October 18, 2021 its initial public offering of 5,000,000 shares of common stock at a price to the public of $14 per share for total gross proceeds of $70,000,000 before deducting underwriting discounts and commissions and estimated offering expenses.
In addition, Lucid has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock from Lucid at the initial public offering price less underwriting discounts and commissions.
Cantor and Canaccord Genuity are acting as joint book-running managers for the offering. BTIG and Needham & Company are acting as co-lead managers for the offering.
